Novel drugs targeting hypertension: Renin inhibitors and beyond

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 1, 2007, Pages 3-8

  Leibovitz, Eyal ^a   Schiffrin, Ernesto L ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Hypertension; Renin inhibitors; Rennin angiotensin aldosterone system

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; OMAPATRILAT; RENIN; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT;

ANGIONEUROTIC EDEMA; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; COUGHING; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; HUMAN; HYPERTENSION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RENIN; RENIN-ANGIOTENSIN SYSTEM; UNITED STATES;

EID: 34547657520     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318093e50d     Document Type: Review

References (58)

1. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560-2572.
2. Hemmelgarn BR, McAlister FA, Myers MG, et al. Canadian Hypertension Education Program, The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I - Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol. 2005;21:645-656.
3. Johnston CI, Millar JA, McGrath BP, et al. Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension. Lancet. 1979;2:493-496.
4. De Venuto G, Andreotti C, Mattarei M, et al. Long-term captopril therapy at low doses reduces albumin excretion in patients with essential hypertension and no sign of renal impairment. J Hypertens Suppl. 1985;3:S143-S145.
5. Packer M, Medina N, Yushak M, et al. Comparative effects of captopril and isosorbide dinitrate on pulmonary arteriolar resistance and right ventricular function in patients with severe left ventricular failure: results of a randomized crossover study. Am Heart J. 1985;109:1293-1299.
6. Chatterjee K, Parmley WW, Cohn JN, et al. A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response. Am Heart J. 1985;110:439-447.
7. Urata H, Kinoshita A, Misono KS, et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265:22348-22357.
8. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-1906.
9. Kehoe B, Keeton GR, Hill C. Elevated plasma renin activity associated with renal dysfunction. Nephron. 1986;44:51-57.
10. Neves MF, Virdis A, Schiffrin EL. Resistance artery mechanics and composition in angiotensin II-infused rats: effects of aldosterone antagonism. J Hypertens. 2003;21:189-198.
11. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension. 2000;35:1270-1277.
12. Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109:1417-1427.
13. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol. 2005;289:H1560-566.
14. Benter IF, Yousif MH, Cojocel C, et al. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol. 2007;292:H666-H6672.
15. Santos RA, Castro CH, Gava E, et al. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension. 2006;47:996-1002.
16. Moreau ME, Garbacki N, Molinaro G, et al. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci. 2005;99:6-38.
17. De Gennaro Colonna V, Rigamonti A, Fioretti S, et al. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats. Eur J Pharmacol. 2005;516:253-259.
18. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens. 2006;15:152-158.
19. Schieffer B, Luchtefeld M, Braun S, et al. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res. 2000;87:1195-1201.
20. Hernandez-Presa M, Bustos C, Ortego M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997;95:1532-1541.
21. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 2003;285:R277-R297.
22. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000;52:639-672.
23. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 1995;95:995-1001.
24. Widdop RE, Jones ES, Hannan RE, et al. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol. 2003;140:809-824.
25. Naruse M, Tanabe A, Sato A, et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension. 2002;40:28-33.
26. D'Amore A, Black MJ, Thomas WG. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension. 2005;46:1347-1354.
27. Esteban V, Ruperez M, Sanchez-Lopez E, et al. Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells. Circ Res. 2005;96:965-973.
28. Burckle C, Bader M. Prorenin and its ancient receptor. Hypertension. 2006;48:549-551.
29. Saris JJ, 't Hoen PAC, Garrelds IM, et al. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension. 2006;48:564-571.
30. Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006;69:105-113.
31. Wang XJ, Han G, Owens P, et al. Role of TGF beta-mediated inflammation in cutaneous wound healing. J Investig Dermatol Symp Proc. 2006;11:112-117.
32. Saunier EF, Akhurst RJ. TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets. 2006;6:565-578.
33. Howell JE, McAnulty RJ. TGF-beta: its role in asthma and therapeutic potential. Curr Drug Targets. 2006;7:547-565.
34. Topper JN. TGF-beta in the cardiovascular system: molecular mechanisms of a context-specific growth factor. Trends Cardiovasc Med. 2000;10:132-137.
35. Burckle C, Danser AHJ, Müller DN, et al. Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension. 2006;47:552-556.
36. Helmer OM. Studies on renin antibodies. Circulation. 1958;17(4, Part 2):648-652.
37. Frishman WH, Fozailoff A, Lin C, et al. Renin inhibition: a new approach to cardiovascular therapy. J Clin Pharmacol. 1994;34:873-880.
38. Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003;308:698-705.
39. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006 21;368:1449-1456.
40. Jeunemaitre X, Menard J, Nussberger J, et al. Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients. Am J Hypertens. 1989;2:819-827.
41. Kleinert HD, Martin D, Chekal MA, et al. Effects of the renin inhibitor A-64662 in monkeys and rats with varying baseline plasma renin activity. Hypertension. 1988;11:613-619.
42. Fisher ND, Allan D, Kifor I, et al. Responses to converting enzyme and renin inhibition: role of angiotensin II in humans. Hypertension. 1994;23:44-51.
43. Verburg KM, Kleinert HD, Chekal MA, et al. Renal hemodynamic and excretory responses to renin inhibition induced by A-64662. J Pharmacol Exp Ther. 1990;252:449-455.
44. van Paassen P, de Zeeuw D, Navis G, et al. Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol Dial Transplant. 2000;15:637-643.
45. Zhang Q, Kohara K, Qui HY, et al. Comparative effects of three sites of renin-angiotensin blockade on the regression of left ventricular hypertrophy in spontaneously hypertensive rats. Am J Ther. 1997;4:199-202.
46. Mento PF, Maita ME, Murphy WR, et al. Comparison of angiotensin converting enzyme and renin inhibition in rats following myocardial infarction. J Cardiovasc Pharmacol. 1993;21:791-796.
47. Kiowski W, Beermann J, Rickenbacher P, et al. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition. Circulation. 1994;90:2748-2756.
48. Parsons KK, Coffman TM. The renin-angiotensin system: it's all in your head. J Clin Invest. 2007;117:873-876.
49. Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension. 2005;46:569-576.
50. Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003;42:1137-1143.
51. O'Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension. 2007;49:276-284.
52. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective Renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11-20.
53. Nussberger J, Wuerzner G, Jensen C, et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39:E1-E8.
54. Dieterle W, Corynen S, Vaidyanathan S, et al. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther. 2005;43:527-535.
55. Davies L, Fulcher GR, Atkins A, et al. The relationship of prorenin values to microvascular complications in patients with insulin-dependent diabetes mellitus. J Diabetes Complications. 1999;13:45-51.
56. 1 antagonism on coronary microvasculature in spontaneously hypertensive rats. Am J Hypertens. 2003;16:931-937.
57. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103-111.
58. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920-926.